{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 458638350
<!-- Monoclonal antibody data -->
| type = mab
| mab_type = mab
| source = xi/o
| target = GD3 [[ganglioside]]
<!-- Clinical data -->
| tradename = 
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B / C / D / X -->
| pregnancy_category = 
| legal_AU = <!-- Unscheduled / S2 / S4 / S8 -->
| legal_UK = <!-- GSL / P / POM / CD -->
| legal_US = <!-- OTC / Rx-only -->
| legal_status = 
| routes_of_administration = 
<!-- Pharmacokinetic data -->
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life = 
| excretion = 
<!-- Identifiers -->
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = none
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 292819-64-8
| ATC_prefix = none
| ATC_suffix = 
| ATC_supplemental = 
| PubChem = 
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = 
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = M76FX2JZRM
<!-- Chemical data -->
| chemical_formula = 
| molecular_weight = 145,255 g/mol
}}

'''Ecromeximab''' is a [[Fusion protein|chimeric]] [[monoclonal antibody]] being developed for the treatment of [[malignant melanoma]].<ref>[http://www.ama-assn.org/ama/upload/mm/365/ecromeximab.doc Statement On A Nonproprietary Name Adopted By The USAN Council - Ecromeximab], ''American Medical Association''.</ref><ref>{{ClinicalTrialsGov|NCT00679289|Phase II Study of KW2871 Combined With High Dose Interferon-alpha2b in Patients With Metastatic Cutaneous Melanoma}}</ref>

The drug was developed by [[Kyowa Hakko Kogyo Co.]], Ltd.  As of December 2015 development had been discontinued.<ref>[http://adisinsight.springer.com/drugs/800013219 Adis insight: Ecromeximab]</ref>

== References ==
<references/>

{{Monoclonals for tumors}}

[[Category:Monoclonal antibodies]]
[[Category:Abandoned drugs]]

{{monoclonal-antibody-stub}}
{{antineoplastic-drug-stub}}